1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. E-therapeutics plc
  6. Company
    ETX   GB00B2823H99


Delayed London Stock Exchange  -  05/17 05:38:57 am EDT
22.76 GBX   -2.11%
05/04Earnings Flash (ETX.L) E-THERAPEUTICS Posts FY22 Revenue GBP477,000
05/04Earnings Flash (ETX.L) E-THERAPEUTICS Posts FY22 Loss GBX-1.65
05/04E-therapeutics plc Announces Change of Registered Office
Business Summary
Logo e-therapeutics plc
e-Therapeutics Plc provides computer-based drug discovery platform. The Company's platform is a combination of databases and a suite of computational tools that employ network analysis, data mining, machine learning, artificial intelligence (Al) and optimization. Its in silico platform serves as a laboratory, which enables it to computationally test potential therapeutic interventions. Its network-driven drug discovery (NDD) technology performs computational phenotypic screens to identify efficacious drugs. Its genome-associated interactions networks (GAINs) technology interprets genomic data in the context of the biological networks, in which the genes function. Its ribonucleic acid (RNA) Interference, (RNAi) platform is in development to complement its computational toolset. The Company identifies new therapeutic approaches to modulate a specific mechanism involved in Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic indications through Galapagos NV (Galapagos).
Sales per Business
Drug Discovery0.32100%0.48100% +50.47%
GBP in Million
Sales per region
United Kingdom0.32100%0.48100% +50.47%
GBP in Million
Name Title Age Since
Ahmad Ali Mortazavi Chief Executive Officer & Director 50 2020
Michael Anthony Bretherton Chief Financial Officer & Director 65 2021
Alan Whitmore, Dr. Chief Scientific Officer - -
Jonny Wray, Dr. Chief Technology Officer - -
Laura Roca-Alonso, Dr. Chief Business Officer - 2020
Stephanie Maley Chief People Officer - 2020
Members of the board
Name Title Age Since
Trevor Mervyn Jones, Dr. Independent Non-Executive Chairman 79 2021
Ahmad Ali Mortazavi Chief Executive Officer & Director 50 2020
Michael Anthony Bretherton Chief Financial Officer & Director 65 2021
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 514,571,069 185,301,334 36.0% 0 0.0% 36.0%
Richard Ian Griffiths 118,539,105 23.0%
Robert Quested 68,320,000 13.3%
Jarvis Investment Management Ltd. 62,239,000 12.1%
Ahmad Ali Mortazavi 50,941,666 9.90%
M&G Investment Management Ltd. 34,375,000 6.68%
Trillian Ltd. 30,454,847 5.92%
Credit Suisse Asset Management (Schweiz) AG 29,730,000 5.78%
David Richardson 24,779,030 4.82%
Lombard Odier Asset Management (Europe) Ltd. 20,265,820 3.94%
Schroder Investment Management Ltd. 14,190,000 2.76%
Company contact information
e-Therapeutics Plc
17 Blenheim Office Park
Long Hanborough, Oxfordshire OX29 8LN

Phone : +44.199.3880000
Fax : +44.199.3880207
Web : http://www.etherapeutics.co.uk
Brand Portfolio
In partnership withAllbrands.markets
More brands of e-therapeutics plc